Life science companies are increasingly turning to international arbitration as a preferred dispute-resolution mechanism due to its confidentiality, comparative cost-effectiveness, and nearly universal enforceability. Evidence illustrates an uptick in arbitrations in the life sciences industry, with the International Chamber of Commerce reporting that health and pharmaceutical disputes have more than doubled between 2015 and 2020. Similarly, the American Arbitration Association saw a 40% increase in the number of life sciences cases filed in 2019.